Bone metastases remain a serious health concern because of limited therapeutic options. Here, we report that crosstalk between ROR1-HER3 and the Hippo-YAP pathway promotes breast cancer bone metastasis in a long noncoding RNA-dependent fashion. Mechanistically, the orphan receptor tyrosine kinase ROR1 phosphorylates HER3 at a previously unidentified site Tyr1307, following neuregulin stimulation, independently of other ErbB family members. p-HER3 Tyr1307 recruits the LLGL2-MAYA-NSUN6 RNA-protein complex to methylate Hippo/MST1 at Lys59. This methylation leads to MST1 inactivation and activation of YAP target genes in tumour cells, which elicits osteoclast differentiation and bone metastasis. Furthermore, increased ROR1, p-HER3 Tyr1307 and MAYA levels correlate with tumour metastasis and unfavourable outcomes. Our data provide insights into the mechanistic regulation and linkage of the ROR1-HER3 and Hippo-YAP pathway in a cancer-specific context, and also imply valuable therapeutic targets for bone metastasis and possible therapy-resistant tumours.
Bone metastasis continues to be a severe health concern although significant progress has been made. When bone metastatic lesions develop, bone residential tumour cells produce a cohort of osteolytic factors 1 . These osteolytic factors, including connective tissue growth factor (CTGF), trigger differentiation of osteoclast precursors derived from monocytes 2 . CTGF is one of the signature genes that are significantly upregulated in patients with relapse to the bone compared with patients with relapse elsewhere according to gene expression analysis 3 . The Hippo-YAP pathway controls cell proliferation, tumorigenesis, chemoresistance and metastasis in human tumours [4] [5] [6] . The core Hippo cassette comprises an MST1/2 (Hippo), LATS1/2 (large tumour suppressor kinase1/2), and YAP (yes-associated protein) signalling cascade 7, 8 . MST1/2 is a protein serine/threonine kinase that negatively regulates cell growth, and mutation of the Hippo genes leads to organ overgrowth 9, 10 . In mammals, MST1/2 phosphorylates LATS1/2, which further phosphorylates YAP for cytoplasmic sequestration and degradation 11 . When MST1/2 kinase activity is inhibited, by an unknown mechanism, YAP accumulates in the nucleus for transcriptional activation 12 .
The receptor tyrosine kinase (RTK)-like orphan receptors (RORs), like all other RTKs 13 , possess an extracellular ligand-binding domain, yet their ligands, cellular effects, and downstream signalling pathways are largely unknown 14 . The two ROR family members, ROR1 and ROR2, were originally found to be involved in skeletal, cardiorespiratory and neurological development 15, 16 . Increasing evidence has indicated that both ROR proteins are highly expressed in multiple human cancer types, including leukaemia, ovarian cancer and breast cancer [17] [18] [19] [20] [21] [22] . Although ROR1 was treated as a pseudokinase originally, on the basis of the observation that ROR1 was unable to be autophosphorylated 23, 24 , some studies have also demonstrated the moderate autocatalytic kinase activity of ROR1 in vitro [25] [26] [27] . The mechanisms of the enzymatic activity, substrates and downstream signalling pathway of ROR1 are still elusive.
Cytoplasmic long noncoding RNAs (lncRNAs) are involved in regulating messenger RNA stabilization and transport as well as microRNA sponging [28] [29] [30] [31] . It has also been suggested that cytoplasmic lncRNAs are important mediators of intracellular signalling pathways. For example, lnc-DC modulates the phosphorylation status of STAT3 32 , NKILA regulates IkB phosphorylation and degradation 33 , and LINK-A regulates HIF1α signalling 34 .
Here, we demonstrate that neuregulin-1 (NRG1) triggers the heterodimerization of ROR1 and HER3, leading to HER3 phosphorylation by ROR1 at Tyr1307. Phosphorylated HER3 recruits the adaptor protein LLGL2, lncRNA MAYA (MST1/2-antagonizing for YAP activation), and methyltransferase NSUN6, which methylates MST1 at Lys59. The methylation abolishes MST1 kinase activity and activates YAP and target genes. These events lead to cancer cell-induced osteoclast differentiation and bone resorption. Our studies identify the crosstalk between the ROR1/HER3-LLGL2-MAYA-NSUN6 signalling axis and the Hippo-YAP pathway, and suggest a promising therapeutic strategy for bone metastatic patients.
RESULTS

ROR1 promotes the colonization and growth of breast cancer cells within the bone
Enhanced ROR1 level has been observed in many blood and solid malignancies. To access its function and regulation under a tumourspecific context, we first surveyed the genetic alterations of the ROR1 gene. In sarcoma, ovarian, pancreatic, breast and lung cancer types, the ROR1 locus is amplified in 2-6% of patients (Fig. 1a) . In breast cancer, the ROR1 locus is amplified in the triple-negative breast cancer (TNBC) subtype compared with the status of other biomarkers ( Supplementary Fig. 1a ). ROR1 expression is significantly upregulated in TNBC compared with non-TNBC subtypes ( Fig. 1b and Supplementary Fig. 1b ). Immunohistochemical (IHC) staining of breast cancer tissue microarrays (TMAs) revealed that high levels of ROR1 correlated with the TNBC subtype and poor survival (Fig. 1c,d and Supplementary Table 1) . Furthermore, ROR1 expression is more correlated with non-small cell lung carcinoma (NSCLC) than with small cell lung carcinoma ( Supplementary Fig. 1c ). To enable functional characterization of ROR1, we generated ROR1 knockout (KO) breast cancer cell lines using CRISPR-Cas9 technology ( Supplementary Fig. 1d ,e). Two individual clones of the ROR1 KO breast cancer cell line exhibited reduced proliferation ( Supplementary  Fig. 1f,g ). ROR1 KO also inhibited migration and invasion of breast cancer cells, and overexpression of wild-type (WT) ROR1, but not the kinase-dead K506A mutant 27 , rescued the migration and invasion of ROR1 KO cells ( Supplementary Fig. 1h-k) .
It has recently been reported that ROR1 mediates alternative Wnt signalling to activate the YAP pathway for organ development 35 , which prompts us to examine the expression of YAP1-regulated genes [36] [37] [38] [39] in ROR1 KO cells. Significantly, the expression of 37 out of the 57 YAP1-regulated genes was downregulated by depletion of ROR1 (Fig. 1e) . Activation of YAP has been shown to promote tumour progression and metastasis 40, 41 . Furthermore, YAP1-regulated genes including CTGF may play important roles in promoting osteolysis during bone metastatic lesion development 42 . Consistently, we found hyper-activation of the YAP pathway and elevated expression of CTGF in bone metastatic BoM-1833 cells 3 compared with parental MDA-MB-231 cells. Interestingly, the ROR1 protein level is upregulated in BoM-1833 cells, and ROR1 KO reduced CTGF production (Fig. 1f,g ). Then we determined the role of ROR1 in cancer cell-induced osteoclast differentiation. We found that the differentiation of osteoclast precursors to mature osteoclasts was stimulated with conditioned media (CM) from parental but not ROR1 KO BoM-1833 cells, and this impaired osteoclast differentiation was rescued by CM from ROR1 KO cells expressing WT ROR1 but not K506A mutant (Fig. 1h,i) . Interestingly, CM from ROR1 KO BoM-1833 cells supplemented with recombinant CTGF rescued osteoclast differentiation ( Supplementary Fig. 1l and Fig. 1j) .
Next, we aimed to determine the role of ROR1 in breast cancer bone metastasis. BoM-1833 cells, containing a stably expressed firefly luciferase reporter, were inoculated to nude mice via intracardiac injection, and metastatic progression was monitored weekly by bioluminescence imaging (BLI). The tumour burden of mouse limbs was greatly reduced by ROR1 KO (Fig. 1k,l) . The bone metastatic lesion number was also decreased when ROR1 was knocked out (Fig. 1m) . Therefore, these data suggest the important role of ROR1 in promoting the colonization and growth of breast cancer cells within the bone through regulation of the Hippo-YAP pathway.
ROR1 phosphorylates HER3 at Tyr1307 in an ErbB-independent manner
To identify the potential substrates or regulators of ROR1, we immunoprecipitated endogenous ROR1 and identified ROR1-binding proteins by mass spectrometry (MS). Interestingly, we found that HER3 was the top protein that binds ROR1 (Supplementary Fig. 2a and Supplementary Table 2 ). The ROR1-associated HER3 harboured a previously unknown phosphorylation site of Tyr1307 (Fig. 2a  and Supplementary Table 2 ). Hence, we generated phosphorylationspecific antibodies targeting p-HER3 (Tyr1307) ( Supplementary  Fig. 2b ) for further cellular and tissue studies.
It has been well established that HER3 forms heterodimers with EGFR and HER2 in response to NRG1 and plays important roles in a variety of cancer types 43, 44 . We hypothesized that ROR1 and HER3 might form heterodimers, and found that HER3 associated with EGFR, HER4 and ROR1 following NRG1 stimulation (Fig. 2b) . NRG1 triggered the phosphorylation at previously known HER3 tyrosine sites (Tyr1197, Tyr1222, Tyr1289 and Tyr1328) 45 as well as at a previously unknown Tyr1307 site (Fig. 2c) . Although the pan-EGFR inhibitor dacomitinib (PF299804) abolished HER3 phosphorylation at those four tyrosine sites, neither tyrosine phosphorylation of Tyr1307 nor the ROR1-HER3 interaction was affected by this inhibitor (Fig. 2d) . In contrast, ROR1 knockdown abolished phosphorylation of HER3 at Tyr1307 but not at the EGFR-dependent phosphorylation sites (Fig. 2e) .
Next, we found that knockdown of EGFR showed minimal effects on the ROR1-HER3 interaction or the status of p-HER3 (Tyr1307) (Fig. 2f ). NRG1 stimulation triggered interaction between exogenous ROR1 and HER3, as well as p-HER3 (Tyr1307) in ERBB-null 32D cells (Fig. 2g) , suggesting a possibility that ROR1 may directly phosphorylate HER3. In vitro kinase assay showed that full-length . (k-m) Representative BLI images (k), BLI signal quantification (l, n = 10 mice per group) and metastatic tumour numbers (m) of mice intracardially injected with parental or ROR1 KO BoM-1833 cells at week 5. For e,g,i,j,l and m, mean ± s.e.m. were derived from n = 3 independent experiments (NS (not significant), P > 0.05; * P < 0.05; * * P < 0.01; * * * P < 0.001; two-tailed paired Student's t-test). Unprocessed original scans of all blots with size markers for f are shown in Supplementary  Fig. 9 . Statistics source data for d,h,i,k and l are in Supplementary  Table 8 . (Fig. 1c) with that of p-HER3 (Tyr1307) within the TNBC subgroup. Fisher's exact test was used (n = 23 patients, P < 0.001; R 2 , correlation coefficient). Unprocessed original scans of all blots with size markers are shown in Supplementary Fig. 9 . Statistics source data for l are in Supplementary Table 8 .
(FL) ROR1 but not the extracellular domain (ECD) phosphorylated the HER3 intracellular domain (ICD) at the Tyr1307 site (Fig. 2h) . Consistently, bacterially expressed ICD of WT ROR1, but not K506A mutant, phosphorylates HER3 at Tyr1307 in vitro (Fig. 2i) . In breast cancer cells, expression of ROR1 K506A mutant abolished Tyr1307 phosphorylation of HER3 following NRG1 stimulation (Fig. 2j) .
It has been reported that ROR1 is tyrosine phosphorylated by c-MET and SRC at the proline-rich domain and the kinase domain, respectively 46 . Our data indicated that neither the tyrosine phosphorylation of ROR1 nor the ROR1-SRC/MET interaction was affected by NRG1 stimulation (Supplementary Fig. 2c ). Although ROR1 tyrosine phosphorylation was abolished by an SRC inhibitor, saracatinib, the NRG1-induced p-HER3 (Tyr1307) was not significantly affected ( Supplementary Fig. 2d) . In 32D cells, ROR1 exhibited undetectable tyrosine phosphorylation and association with SRC ( Supplementary  Fig. 2e ), suggesting that the NRG1-triggered ROR1-HER3 pathway is independent of EGFR-SRC-MET signalling in breast cancer cells.
High levels of HER3 expression correlate with unfavourable outcomes for TNBC patients 47, 48 . To ascertain whether p-HER3 (Tyr1307) promotes proliferation and invasion of breast cancer cells, we knocked out HER3 and found that HER3 KO impaired cell proliferation and mobility ( Supplementary Fig. 2f-k) . p-HER3 (Tyr1307) is highly increased in TNBC compared with other breast cancer subtypes (Fig. 2k) . Further, the p-HER3 (Tyr1307) correlates with breast cancer patient outcomes (Fig. 2l) . Interestingly, the level of ROR1 in TNBC strongly correlates with p-HER3 Tyr1307 status (R 2 = 0.839) (Fig. 2m) . Furthermore, the p-HER3 (Tyr1307) is elevated in lung adenocarcinomas compared with normal lung tissues ( Supplementary  Fig. 2l) ; lung adenocarcinomas at the metastatic stage (TnN>0M≥0) showed an increased p-HER3 (Tyr1307) level compared with the non-metastatic stage (TnN0M0) (Supplementary Fig. 2l) . A high level of p-HER3 (Tyr1307) also correlates with unfavourable outcomes for lung adenocarcinoma patients ( Supplementary Fig. 2m ).
Crosstalk between ROR1-HER3 and Hippo-YAP pathway Phosphorylation of a receptor tyrosine kinase triggers the recruitment of proteins that contain an SH2 domain to mediate downstream signalling 49 . The SH2-domain-containing protein BCAR3 (breast cancer anti-oestrogen resistance 3) identified by MS (see Supplementary Fig. 2a ) could be recruited to p-HER3 (Tyr1307). To test this, we mutated HER3 Tyr1307 to phenylalanine (Y1307F) and Tyr1197/Tyr1222/Tyr1289/Tyr1328 to phenylalanine (4Y-F). We found that the expression of the HER3 Y1307F mutant, but not the 4Y-F mutant, abolished the HER3-BCAR3 interaction following NRG1 stimulation (Fig. 3a) . Consistently, the deletion of the SH2 domain of BCAR3 abolished the HER3-BCAR3 interaction but showed no effect on p-HER3 (Tyr1307) (Fig. 3b) . Next, we synthesized biotinylated-HER3 peptides harbouring either phosphorylated or unphosphorylated Tyr1197, Tyr1222, Tyr1289, Tyr1328 and Tyr1307 residues with their corresponding flanking amino acid sequences. Streptavidin pulldown showed that the HER3 peptide harbouring pTyr1307, but not other p-Tyr residues, strongly interacts with BCAR3 (Fig. 3c) .
We further investigated the downstream signalling pathways of BCAR3. Recombinant protein pulldown assay indicated that BCAR3 directly binds LLGL2 (lethal giant larvae homologue 2) but not other proteins identified by MS (Fig. 3d) . In Drosophila, the adaptor protein LLGL2 plays a critical role in mediating the Hippo-YAP pathway regulated by cell-cell junctions 50 . Our MS confirmed the associations of ROR1, HER3 and BCAR3 with LLGL2 ( Supplementary Fig. 3a) . Furthermore, a panel of Hippo complex proteins (STK4 (MST1), SAV1, MOB1 and RASSF1 (Ras association domain family member 1)) were observed to bind both ROR1 and LLGL2 ( Supplementary  Fig. 3a and Supplementary Table 3 ). MS also revealed the LLGL2 phosphorylation at Tyr499; thus, a site-specific antibody against p-LLGL2 (Tyr499) was generated ( Supplementary Fig. 3b,c) . ROR1 was the most plausible candidate for LLGL2 (Tyr499) phosphorylation in the context of this specific signalling cascade, and in vitro kinase assay confirmed this hypothesis (Fig. 3e) . Consistently, overexpression of the kinase-dead mutant of ROR1 abolished phosphorylation of LLGL2 at Tyr499 in NRG1-treated cells (Supplementary Fig. 3d ). Knockdown of BCAR3 eliminated the interaction between HER3 and LLGL2 as well as p-LLGL2 (Tyr499) (Fig. 3f) . GST-LLGL2 pulldown showed that both non-phosphorylated (No-P-) and phosphorylated (P-) LLGL2 bind BCAR3, but only P-LLGL2 (Tyr499) binds MST1 (Fig. 3g) .
A previously unknown dimethylation modification of MST1 at Lys59 (MST1 (Lys59me2)) was also identified from MS and confirmed by methylation-specific antibodies ( Supplementary Fig. 3e and Supplementary Table 3 and Supplementary Fig. 3f ). Lysophosphatidic acid (LPA) has been shown to trigger YAP1 activation via G-proteincoupled receptor signalling 51 . Our data showed that NRG1, but not LPA, triggered MST1 (Lys59me2), and MST1 methylation status negatively correlates with MST1 (Thr183) phosphorylation and YAP1 (Ser127) phosphorylation ( Fig. 3h and Supplementary Fig. 3g ).
LncRNA MAYA is involved in YAP activation
We found a putative protein methyltransferase, NSUN6, in both ROR1 and LLGL2 pulldown experiments (see Supplementary Fig. 2a  and 3a) . NSUN6 is an RNA-binding ribosomal protein that can mediate RNA methylation 52 . Therefore, we hypothesized that lncRNA molecules could associate with NSUN6 to regulate MST1 methylation. To identify the lncRNAs that might be involved in the YAP signalling pathway, we transfected the human Lincode siRNA library into MCF-7 cells that were engineered with a TEAD-driven luciferase reporter, and subsequently the relative YAP1 activity was determined. We set up a threshold at log 2 ≤ -3 (red line) to pinpoint 40 lncRNAs that were potentially required for YAP1-dependent transcription ( Fig. 4a and Supplementary Table 4) .
We then picked up the top five lncRNAs for RNA pulldown experiments to identify whether they bind the Hippo-YAP pathway proteins. Interestingly, LOC645249 (MNX1-AS1) binds LLGL2, MST1, SAV1, MOB1, NSUN6 and RASSF1, suggesting that it may mediate the YAP pathway activation; thus, we renamed this lncRNA as MST1/2-antagonizing lncRNA for YAP activation (MAYA) ( Supplementary  Fig. 4a and Supplementary Table 5 ). We performed a 5 -and 3 -rapid amplification of cDNA ends (RACE) assay to determine the entire sequence of MAYA, confirming that the sequence detected in MDA-MB-231 cells is identical to that archived in the RefSeq database ( Supplementary Fig. 4b ). The expression pattern and splicing variation of MAYA in human tissues and breast cancer cells were validated by northern blot (Supplementary Fig. 4c,d) .
The Cancer Genome Atlas (TCGA) database mining revealed that MAYA expression is upregulated in breast cancer compared with normal tissue in both matched and unmatched sample pools (Fig. 4b) . In addition, RNAscope analysis confirmed that 71% and 62% of breast cancer tissues exhibited positive MAYA staining in training and validation studies respectively (Fig. 4c) . Furthermore, MAYA expression in breast cancer is associated with advanced GST WT ECD GST WT ECD stage (TnN>0M≥0) (P = 0.049) ( Fig. 4d ) and unfavourable patient outcomes (P = 0.0085) (Fig. 4e) . As revealed by RNAscope 2.0 analysis, MAYA was upregulated in the majority of human solid tumours ( Supplementary Fig. 4e ). High levels of MAYA also correlate with lung adenocarcinoma, metastatic stage (TnN>0M≥ 0) and poor outcomes ( Supplementary Fig. 4f,g ).
We next tested whether MAYA is required for YAP1 activation in this specific signalling context, finding that MAYA depletion significantly impaired the occupancy of YAP1 on the promoter of its target genes ( Fig. 4f) and expression of these genes under NRG1 stimulation ( Fig. 4g,h ). The phosphorylations of MST1 (Thr183), MOB1 (Thr35), LATS1 (Thr1079) and YAP (Ser127) were all Percentage of input For b and h, the boxes show the median ± 1 quartile, with whiskers extending to the most extreme data point within 1.5 interquartile ranges from the box boundaries. For d,f,g,j,l and m, mean ± s.e.m. were derived from n = 3 independent experiments (NS (not significant), P > 0.05; * P < 0.05; * * P < 0.01; two-tailed paired Student's t-test). Unprocessed original scans of all blots with size markers are shown in Supplementary  Fig. 9 . Statistics source data for c and k-l are in Supplementary  Table 8 .
increased following MAYA knockdown (Fig. 4i) . Accordingly, MAYA knockdown significantly reduced CTGF secretion in BoM-1833 cells (Fig. 4j) , and consequently impaired cancer cell-induced osteoclast differentiation and bone resorption, which could be partially rescued by introduction of recombinant CTGF ( Fig. 4k-m) . Notably, MAYA is not involved in LPA or cell-density-dependent YAP1-target-gene regulation ( Supplementary Fig. 4h ,i).
LncRNA-mediated, NSUN6-dependent methylation inhibits the kinase activity of MST1
RNA pulldown in cell lysates showed that only the sense transcript of MAYA binds a panel of Hippo pathway proteins ( Supplementary  Fig. 5a ,b). However, in vitro RNA pulldown with bacterially expressed recombinant proteins revealed that only LLGL2 and NSUN6 directly bind MAYA (Fig. 5a ), and the interactions were further confirmed by RNA immunoprecipitation (RIP) assay (Fig. 5b ). LLGL2 contains 14 WD40 repeats that act as scaffolds to interact with RNA molecules for cellular functions 50, 53 . To map the RNA-binding region of LLGL2, we generated a series of LLGL2 deletion mutants, finding that removal of the first three WD40 domains ( WD [1] [2] [3] ) of LLGL2 abolished the MAYA-LLGL2 interaction (Fig. 5c) . Similarly, the PUA domain of NSUN6 ( 111-203) is required for the MAYA-NSUN6 interaction (Fig. 5d ). The necessity of the WD40 domains 1-3 of LLGL2 and the PUA domain of NSUN6 for MAYA binding was confirmed in vivo by RIP assay (Fig. 5e) .
To characterize the specific RNA sequences required for these interactions, we performed an in vitro RNA pulldown followed by a dot-blot assay as previously described 34, 53 . We found that sequence B1 (nucleotides 241-300) of MAYA is essential for LLGL2 binding, and D3 (nucleotides 841-900) is responsible for NSUN6 binding ( Fig. 5f ), which was further confirmed by RNA pulldown assay with the corresponding MAYA mutants ( Supplementary Fig. 5c and Fig. 5g ). Furthermore, RNA electrophoretic mobility shift assay indicated that the sequences of nucleotides 251-290 and nucleotides 851-890 of MAYA directly bind LLGL2 and NSUN6, respectively (Supplementary Fig. 5d ). Both RNA fluorescence in situ hybridization (FISH) and cell fractionation assay indicated that MAYA is localized to the cytosol ( Fig. 5h and Supplementary Fig. 5e ). Immuno-RNA FISH and RIP assays suggested that MAYA co-localized with LLGL2 following NRG1 stimulation, which was impaired in the presence of the LLGL2 Y499F mutant (Fig. 5h,i) .
In the presence of FL MAYA, but not the LLGL2 or NSUN6 deletion transcripts, bacterially expressed LLGL2 could pulldown NSUN6 in vitro (Fig. 6a) . These experiments suggested that the LLGL2-MAYA-NSUN6 complex might be responsible for MST1 methylation on Lys59. To test this, we performed an in vitro protein methylation assay and observed that only NSUN6 was able to methylate MST1 in the presence of SAM (S-adenosyl methionine) (Fig. 6b) . Lys59 of MST1, in charge of ATP-binding, is critical for the kinase activity and autophosphorylation of MST1 54 . We found that mutation of MST1 Lys59 to alanine or knockdown of NSUN6 impaired NRG1-triggered MST1 methylation at Lys59 (Fig. 6c,d ). Consistently, knockout of LLGL2 or knockdown of MAYA abolished the methylation of MST1, leading to hyperphosphorylation of MST1 at Thr183 (Fig. 6e,f) .
We further investigated the regulatory roles of LLGL2 and NSUN6 in modulating MST1 methylation. We found that both the LLGL2 Y499F and WD 1-3 deletion mutants abolished ligand-induced MST1 methylation (Fig. 6g ). In addition, unphosphorylated LLGL2 (Y499F) still associated with NSUN6, but failed to recruit MST1 (Fig. 6g) while the WD 1-3 LLGL2 mutant could recruit MST1, but failed to associate with NSUN6 ( Fig. 6g) . Similarly, expression of both the NSUN6 SAM ( 242-248) and the PUA ( 111-203) mutants impaired MST1 methylation in vivo (Fig. 6h) . To validate the hypothesis that methylation at Lys59 abolishes the kinase activity and autophosphorylation of MST1, we performed an in vitro methylation followed by a kinase assay. In the presence of SAM, methylated MST1 failed to be phosphorylated at Thr183, but the unmethylated MST1 was autophosphorylated at Thr183 in the presence of ATP (Fig. 6i) . At the cellular level, LLGL2 KO but not NSUN6 KO, decreased cell proliferation ( Supplementary Fig. 6a-d) . However, both LLGL2 and NSUN6 KO reduced cell mobility ( Supplementary Fig. 6e-h ). Among 57 YAP1-regulated genes examined, NRG1-induced expression of 25, 37, 40 and 29 genes was significantly downregulated by ROR1 KO, LLGL2 KO, NSUN6 KO and HER3 KO, respectively, and 21 genes were commonly reduced (Fig. 6j) . Thus, we have identified the crosstalk between the ROR1/HER3-LLGL2-MAYA-NSUN6 signalling axis and the Hippo pathway.
To further demonstrate the mechanistic linkage, we expressed WT ROR1 and the K506A mutant in ROR1 KO cells for rescue experiments. We found that the expression of WT ROR1, but not the K506A mutant, restored the NRG1-triggered phenotypes (Fig. 7a) . Furthermore, we performed rescue experiments using HER3 Y1307E and LLGL2 Y499E phosphorylation-mimic mutants, respectively. The HER3 Y1307E mutant mediated the HER3-BCAR3 interaction and recruitment of LLGL2 to phosphorylated HER3 ( Fig. 7b and Supplementary Fig. 7a ), and expression of the LLGL2 Y499E mutant in ROR1 KO cells rescued MST1 methylation and YAP1 hypophosphorylation ( Supplementary Fig. 7a and Fig. 7c ), and activation of YAP1 target genes in the absence of NRG1 (Fig. 7d and Supplementary Fig. 7b,c) .
Next, we knocked down MAYA by the locked nucleic acid (LNA) method and rescued the expression of MAYA using LNAresistant FL MAYA or LLGL2 and NSUN6 mutants, respectively ( Supplementary Fig. 7d,e) . MAYA knockdown in both breast and lung cancer cells showed dramatic effects on NRG1-dependent MST1 (Lys59) methylation, but minimal effects on phosphorylations of HER3 (Tyr1307) and LLGL2 (Tyr499) (Fig. 7e and Supplementary  Fig. 7f ). The NRG1-induced expression of YAP1-regulated genes was attenuated in MAYA knockdown cells but rescued by expressing FL MAYA, but not LLGL2 and NSUN6 deletion mutants in these cells (Fig. 7f and Supplementary Fig. 7g,h ). As a control, an NRG1-induced gene, ETS2
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, was not affected by MAYA knockdown (Supplementary Fig. 7i ). Furthermore, CM from MAYA knockdown cells failed to enhance osteoclast differentiation ( Fig. 7g and Supplementary Fig. 7j ) and bone resorption by osteoclasts (Fig. 7h) . Notably, these effects were rescued by CM from MAYA knockdown cells expressing FL MAYA, but not the LLGL2 and NSUN6 deletion mutants (Fig. 7g,h and Supplementary Fig. 7j ).
MAYA serves as a promising therapeutic target for bone metastasis
We examined the expression level of MAYA in MDA-MB-231 parental and organ-specific metastatic derivatives, including LM2 (i) RIP assay using anti-FLAG antibody in MDA-MB-231 cells transfected with the indicated plasmids followed by NRG1 treatment. For b,e and i, mean ± s.e.m. were derived from n = 3 independent experiments (NS (not significant), P > 0.05; * P < 0.05; * * P < 0.01; * * * P < 0.001; two-tailed paired Student's t-test). Unprocessed original scans of all IB blots with size markers are shown in Supplementary Fig. 9 . For a,c,d,f and g, unprocessed original scans of dot blots are also shown in Supplementary Fig. 9 . Raw images of three independent experiments for h are in Supplementary Table 8 . Twentyone genes were found to be commonly downregulated under all of the KO conditions (n = 3 independent experiments, * P < 0.05, two-tailed paired Student's t-test). Unprocessed original scans of all blots with size markers are shown in Supplementary Fig. 9 .
(lung) 56 , BoM-1833 (bone) 56 , BRN (brain) 57 , and a brain metastatic cell line derived from BT474 and its parental line 58 . We found that MAYA was highly expressed in BoM-1833 cells, suggesting the potential role of MAYA in bone metastasis from breast cancer (Supplementary Fig. 8a ). In BoM-1833 cells, MAYA knockdown showed minimal effects on NRG1-dependent p-HER3 (Tyr1307) and p-LLGL2 (Tyr499), but dramatic effects on MST1 (Lys59me2) and NRG1-triggered hypophosphorylation of MST1, LATS1, YAP1, as Helical peptides (ng ml were derived from n = 3 independent experiments (NS (not significant), P > 0.05; * P < 0.05; * * P < 0.01; two-tailed paired Student's t-test). Unprocessed original scans of all blots with size markers are shown in Supplementary  Fig. 9 .
well as the expression of CTGF (Fig. 8a,b) . Consistently, exogenous expression of FL MAYA, but not the LLGL2 or NSUN6 mutants, in MAYA knockdown BoM-1833 cells rescued these phenotypes (Fig. 8b) . Inducible knockdown of MAYA by shRNAs inhibited proliferation, migration and invasion of BoM-1833 cells ( Supplementary Fig. 8b-e) .
We then investigated the role of MAYA in breast cancer bone metastasis using the intracardiac injection experimental metastasis mouse model. Compared with control shRNA (Ctl), inducible knockdown of MAYA significantly decreased hindlimb tumour burden (Fig. 8c,d ). Micro-computed tomography (Micro-CT) imaging revealed that mice inoculated with MAYA knockdown cells exhibited decreased bone lesions (Fig. 8e) . Quantitative real-time RT-PCR analysis of bone tumour samples from mice inoculated with MAYA knockdown cells revealed a substantial decrease of MAYA expression (Supplementary Fig. 8f ). Specimen CT revealed that MAYA knockdown increased trabecular bone mass in the femur (Fig. 8f) . Quantification analyses confirmed a noteworthy enhancement of bone volume, trabecular thickness, and decreased trabecular spacing, but insubstantial differences in cortical bone thickness when MAYA was depleted (Fig. 8g-j) . Histological TRAP staining indicated that MAYA knockdown impaired the number of osteoclasts relative to bone surface area (Fig. 8k) . Therefore, these data suggest the importance of MAYA in promoting breast cancer metastasis to the bone. 0.8 were derived from n = 3 independent experiments (NS (not significant), P > 0.05; * P < 0.05; * * P < 0.01; two-tailed paired Student's t-test). Unprocessed original scans of all blots with size markers are shown in Supplementary Fig. 9 . Statistics source data for c,d,f-k and m,n can be found in Supplementary Table 8 .
Next, we examined the potential therapeutic value of MAYA LNAs using the same mouse model. After intracardiac inoculation of BoM-1833 cells, nude mice were intravenously injected with scramble (Scr) LNA or LNA targeting MAYA (15 mg kg −1 , three times per week) for three weeks. BLI imaging showed that the bone tumour burden was greatly reduced in mice treated with MAYA LNA (Fig. 8l-n) . The expression level of MAYA from mouse bone metastatic lesions was significantly reduced following MAYA LNA treatment (Fig. 8o) . We further explored the tumour-promoting and bone metastasis function of MAYA in lung cancer using A549-Luc cells and observed similar effects ( Supplementary Fig. 8g-l) .
DISCUSSION
Recent studies have revealed that the activity of YAP/TAZ transcriptional co-activators and LATS1 kinase could be regulated by nutritional stress 59 , GPCR signalling 51 , WNT signalling 35 , and the mevalonate pathway 60 . However, the modulation of the Hippo kinase MST1/2 is not yet understood. Our study found that NRG1-bound ROR1/HER3 heterodimer recruits adaptor LLGL2 and methyltransferase NSUN6 in an lncRNA-dependent fashion. The LLGL2-MAYA-NSUN6 module methylates MST1 at Lys59, which abolishes the kinase activity of MST1 and consequently leads to hypophosphorylation of LATS1 and YAP. YAP is activated and accumulates in the nucleus to stimulate the target gene expression involved in tumour cell proliferation and bone metastasis (Supplementary Fig. 8m ).
Orphan receptor tyrosine kinase ROR1 transduces cellular signalling through both kinase-dependent and -independent mechanisms. ROR1 associates with EGFR, HER3, SRC or c-MET in response to EGF or Wnt stimulation to promote cancer cell proliferation, survival and invasion 27, 46 . Our data indicate that in TNBC cells, ROR1 forms a heterodimer with HER3 to phosphorylate HER3 and LLGL2 following NRG1 stimulation. It is possible that ROR1 dynamically forms heterodimers, or heterotrimers, with other (receptor) tyrosine kinases in the presence of different ligands. ROR1 is subjected to tyrosine phosphorylation by SRC and MET within the kinase domain and proline-rich domain, respectively 46 . Although our data indicate that NRG1 exhibited minimal effect on the tyrosine phosphorylation of ROR1, it is possible that other ligands or signals may induce these modifications and regulate the kinase activity of ROR1. The downstream signalling pathways triggered by ROR1 might vary depending on the cell/tissue types. Previous studies suggested that ROR1 phosphorylates SRC to activate the AKT pathway 20, 27 . Our findings demonstrated the crosstalk between ROR1-HER3 and the Hippo-YAP pathway mediated by lncRNAs under a cancer-specific context. Nuclear ErbB family members have been shown to modulate gene expression as transcriptional co-activators 61 . For example, nuclear ErbB4 has been suggested to associate with YAP and to regulate expression of YAP target genes 62 . It is possible that truncated nuclear HER3 was translocated into the nucleus to trigger the YAP transcriptional program.
The role of MAYA in mediating the LLGL2-NSUN6 interaction is an intriguing paradigm. The complicated secondary structure of long noncoding RNA molecules provides multiple protein binding sites, which may scaffold the RNA-protein complex formation 34, 63 . Given uncharacteristic RNA-binding domains recently identified, such as WD40, SH2 and SH3 domains 64 , we anticipate that lncRNAdependent regulatory mechanisms are widely applicable in signal transduction and epigenetic modifications. Although we show that growth factor enhances the association between LLGL2, MAYA and NSUN6 to methylate MST1, it is worth investigating whether or not the LLGL2-MAYA-NSUN6 complex assembly is regulated by other ligands.
For TNBC and NSCLC patients, anti-EGFR-targeted therapies have been one of the primary treatments. However, a key challenge lies in how to overcome acquired resistance to tyrosine kinase inhibitors (TKIs). Recently, EGFR mutations have been linked to bone metastasis 65 . The highly upregulated ROR1 expression and YAP pathway activation in bone metastatic cells signified the potential therapeutic values of combined targeting of ROR1 and the YAP pathway against bone metastasis. Indeed, ROR1 has been implicated in EGFR-resistance in NSCLC patients 66 . Our observation that breast cancer patients with strong p-HER3 Tyr1307 staining exhibited unfavourable progression-free survival outcomes compared with patients with low HER3 staining suggests that p-HER3 Tyr1307 and MAYA may serve as predictive biomarkers to forecast bone metastasis and refer to commence targeted anti-EGFR therapy. Further, targeting ROR1 using monoclonal antibodies or small-molecule inhibitors may prove to be a promising therapeutic option for leukaemia TNBC, and NSCLC patients. Finally, our study demonstrates the effectiveness of LNA oligonucleotide-based inhibition of breast cancer bone metastasis, which could be further developed as a valuable therapeutic strategy either alone or in combination with EGFR inhibitors, to overcome resistance to EGFR-targeted therapies.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. For treatment, cells were serum starved overnight to 24 h followed by treatment with growth factors (PeproTech), EGF (10 ng ml −1 ), NRG1 (100 ng ml −1 ) or LPA (1 µM, Cayman Chemical) for 30 min or 2 h. Under the specified conditions, cells were pre-treated with the pan-EGFR inhibitor dacomitinib (PF299804, PF299) at 100 nM, the c-SRC inhibitor saracatinib (AZD0530) and the c-MET inhibitor JNJ-38877605 (Selleckchem) at 5 µM for 2 h. siRNA or LNA transfections were performed using DharmaFECT4 (GE Healthcare). Plasmid transfections were performed using Lipofectamine 3000 (Life Technologies). Electroporation of 32D cells with DNA plasmids was performed using the Amaxa 4D-Nucleofector System. Lentiviruses were produced in HEK293T cells with the ViraPower Lentiviral Expression System (Life Technologies) and used to transduce target cells.
Plasmids and constructs.
The FL LLGL2, MST1, NSUN6, BCAR3, HER3 and ROR1 mammalian expression vectors were obtained from Origene Technologies. Bacterial expression vectors for His 6 -HER3 (WT and mutants) and HER3 ICD were constructed by subcloning the corresponding gene sequences into pET-DEST42 vectors using the Gateway system (Life Technologies). GST-tagged LLGL2 (WT and mutants) was constructed into the pGEX-5X-1 backbone (GE Healthcare). Mammalian expression vectors for FL MAYA and mutants were constructed by subcloning the gene sequences into the pBabe backbone (Addgene). To generate the LNA no. 3-resistant MAYA mammalian expression vectors used in the rescue experiments, LNA no. 3-targeting sequences GAG CCT TTG CAA AGA G were mutated to GAG CCT TTC GTA AGA G. All mutants were generated using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies).
Antibodies. The antibodies used in this study are summarized in Supplementary  Table 6 . The specificity of the antibodies was confirmed by peptide competition assay with unphosphorylated/unmethylated peptide, phosphorylated/methylated peptide, or corresponding scrambled phosphorylated/methylated peptide (modified residue was exchanged in position with its adjacent residue). 
Generation of knockout cell lines. CRISPR-
) and DOT1L (L-014900) from GE Healthcare Dharmacon were used in this study. The knockdown efficiency and specificity of all siRNAs were validated by either RT-qPCR or immunoblotting. The shRNAs targeting MAYA were designed using the shERWOOD algorithm and cloned into the UltramiR scaffold in the pZIP lentiviral vector (transOMIC technologies). For in vivo inducible knockdown of MAYA in xenograft experiments, shRNA sequences were constructed into the pZIP-TRE3GS lentiviral vector (transOMIC technologies). LNAs targeting MAYA or a scrambled sequence were designed and synthesized from Exiqon. Supplementary Table 7 contains detailed sequence information for siRNAs, shRNAs and LNAs.
Protein recombination and purification. GST-LLGL2, GST-MST1, BCAR3 and GST-RASSF1 were obtained from Abnova. FLAG-NSUN6, FLAG-SAV1, FLAG-MST1, FLAG-ROR1 (WT and extracellular domain) and FLAG-HER3 were obtained from Origene Technologies. His 6 -MOB1 was purchased from Novoprotein Inc. GST-ROR1 was obtained from SignalChem. His 6 -HER3 intracellular domain (ICD) and WT His 6 -MST1 and corresponding mutants were expressed in the E. coli strain BL21-CodonPlus (DE3)-RIPL (Agilent Technologies) and purified using HisPur Cobalt Spin Columns (Life Technologies). Domain deletion or point mutants of GST-ROR1 ICD and GST-LLGL2 were purified using the Pierce GST Spin Purification Kit (Life Technologies). Biotinylated HER3 and phospho-HER3 peptides were synthesized by Elim Biopharmaceuticals Inc.
Cell lysis, fractionation, immunoprecipitation and immunoblotting. Cells lysis preparation, immunoprecipitation and immunoblotting were performed as previously described 34, 53 . For cell fractionation, cytoplasmic and nuclear fractions were separated using a cytoplasmic and nuclear protein/RNA extraction kit (Thermo Fisher Scientific) following the manufacturer's instructions.
Human CTGF ELISA. The human CTGF levels in the conditioned media of cultured cells were quantitatively determined in triplicate by the OmniKine ELISA kit (Assay Biotechnology).
In vitro osteoclast differentiation. Human osteoclasts were obtained from Lonza and differentiated in vitro according to the vendor's instructions. Conditioned media collected from the KO cells or cells transfected with indicated LNAs/plasmids after 72 h were added to osteoclast cells at day 3 of differentiation in a 6-well plate. In rescue experiments, recombinant CTGF or CCN3 (PeproTech) was supplemented in conditioned media as indicated. Cells were TRAP stained on day 7 using the Acid Phosphatase, Leukocyte (TRAP) kit (Sigma-Aldrich), and TRAP+-multinucleated cells were quantified as mature osteoclasts. Quantitative TRAP assay was performed using the TRACP and ALP assay kit (Takara). For osteoclast resorption function analyses, bone marrow osteoclast differentiation was conducted in OsteoAssay bone plates (Lonza) and osteoclast activity was determined by quantifying the type I collagen helical peptide α1 (I) 620-633 released from bone into culture medium using the MicroVue Bone Helical Peptide EIA assay (Quidel).
Tumour bone metastasis analysis. All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of MD Anderson. Animals arriving in our facility were randomly put into cages with five mice each. They were implanted with respective tumour cells in the unit of cages, which were randomly selected. The animal experiment was set up to use 5-10 mice per group to detect a twofold difference with a power of 80% and at the significance level of 0.05 by a two-sided test for significant studies (RaoSoft Inc. sample size calculator). The luciferase-labelled BoM-1833 or A549-Luc cells (2 × 10 5 ) in 50 µl 1× PBS were intracardially injected into the left ventricle of nu/nu, female 4-6-week-old nude mice using a 100-µl Hamilton Microliter syringe. To induce MAYA shRNA expression, mice were fed with 1 mg ml −1 of tetracycline in drinking water containing 2% sucrose.
To assess the effect of MAYA knockdown with LNA, mice were intravenously injected with in vivo-grade LNAs against MAYA (Exiqon) in PBS (15 mg kg −1 ) three times per week for three weeks after BoM-1833 cells injection. Bone metastases were quantified by BLI every week using an IVIS Spectrum Xenogen Imaging System (Caliper Life Sciences). The osteolytic metastatic lesions on the femurs and tibiae were visualized using the micro-CT imaging. The hindlimbs or other organs were removed and fixed for histological analysis. For the structural analysis of trabecular and cortical bones, mouse femurs and tibias were fixed in 70% ethanol and scanned at 7 µm resolution using the eXplore Locus micro-computed tomography instrument (µCT, GE Healthcare) at the Small Animal Imaging Facility of MDACC. The images were reconstructed and trabecular bone parameters were calculated using the eXplore Utilities software (GE Healthcare). For all animals producing respective tumours, they were randomly divided into groups. No animals were excluded from the analysis. The investigators were not blinded to allocation during experiments and outcome assessment.
RNAi screening. Dharmacon Lincode SMARTpool siRNA Library-Human NR LncRNA RefSeq v54 (no. G-301000) (GE Dharmacon) was used. TEAD-reporter-MCF-7 cells (1 × 10 4 ) were plated in 96-well plates 24 h before transfection. The cells were transfected with either the 15 pmol Lincode siRNA library or siRNA control (GE Healthcare Dharmacon). siGLO green transfection indicator was included to show that over 80% of the cells were transfected using this method. Cells were lysed 72 h after transfection and assayed for luciferase activity using the Dual-Glo Luciferase reporter system (Promega) and activities were monitored by Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek). The protein concentrations of diluted cell lysates (1:100) were measured in parallel using the Bio-Rad protein assay kit (Bio-rad), which was used to normalize the luciferase activity. The firefly luciferase activity for each 96-well plate was subtracted with background, normalized by protein concentration, and further normalized by control siRNA as fold changes. Log 2 of relative fold changes were plotted. The hits with log 2 ≤ −3 were selected as the top candidates.
RNA biology assays. The in vitro transcription, RNA pulldown/mass spectrometry analysis, in vitro RNA-protein binding assay, in vitro RNA pulldown coupled with dot-blot assay and RT-qPCR were performed as previously described 34, 53 . The RNA electrophoretic mobility shift assay was performed as previously described 34, 53 using bacterial recombinant LLGL2 and NSUN6 with synthesized RNA oligonucleotides corresponding to nucleotides 241-300 and nucleotides 841-900 (GE Healthcare Dharmacon). 5 -and 3 -rapid amplification of cDNA ends (RACE) was performed using the SMARTer RACE 5 /3 Kit (Clontech). MAYA RNA expression was detected using the NorthernMax Kit (Ambion) with biotin-labelled LNA probes (Exiqon) in cells and using a pre-made human tissue northern blot (Zyagen). Supplementary Table 7 contains detailed sequence information for primers and probes.
RNAScope assay, immuno-RNA FISH and histological analysis/microscopy. Detection of MAYA expression using the RNAScope probe (designed by Advanced Cell Diagnostics) was performed on breast or lung cancer cell lines and tissue microarrays with the RNAScope 2.0 High Definition Assay kit according to the manufacturer's instructions (Advanced Cell Diagnostics). The images were visualized with the Zeiss Axioskop2 plus Microscope, and the slides were scanned on the Automated Cellular Image System III (ACIS III, Dako) for quantification by digital image analysis.
Immuno-RNA FISH was performed as previously described 34 . In brief, the specimen slides from RNA FISH were blocked with blocking buffer (1× PBS/5% goat serum/0.3% Triton X-100) for 1 h at room temperature followed by incubation with diluted primary antibody in dilution buffer (1× PBS/1% BSA/0.3% Triton X-100) for 2 h at room temperature, then incubated with fluorochrome-conjugated secondary antibody for 1 h at room temperature in the dark, and the slides were rinsed and mounted for visualization.
Immunohistochemistry (IHC) staining was performed as previously described 34, 53 . For Von Kossa staining, slides were stained in 1% silver nitrate followed by a wash, then incubated in formaldehyde, sodium carbonate solution to develop the stain followed by a wash, then placed in 5% sodium thiosulfate solution and rinsed. The slides were counterstained in van Gieson stain. For tartrate-resistant acid phosphatase (TRAP) staining, slides were incubated in acetate buffer of sodium acetate and tartaric aid, pH 5.0 at 37 • C for 20 min; then the substrate naphthol AS-MX phosphate was added, followed by the colour developer, fast red TR hemi (zinc chloride) salt at 37 • C until colour development was observed in TRAP-positive cells. The slides were washed and counterstained in Harris's haematoxylin. Images were acquired with the Zeiss Axioskop2 plus microscope and analysed with ProgRes Capture Pro software. The slides were scanned on the Automated Cellular Image System III (Dako, Agilent) for quantification by digital image analysis.
Image analysis and quantification for RNAScope assay and immunohistochemistry. A total score of MAYA expression was calculated from both the percentage of positive cells and intensity. High and low expression was defined using the mean score of all samples as a cutoff point. Spearman rank correlation was used for statistical analyses of the correlation between each marker and clinical stage. The RNAScope and IHC staining were categorized into five grades 0, 1+, 2+, 3+ and 4+, according to the following criteria: 0) no staining or less than 5% tumour cells in each field (three fields) examined; 1+) 5%-10% tumour cells have staining in each field (three fields) examined; 2+) 10%-25% tumour cells have staining in each field (three fields) examined; 3+) 25%-50% tumour cells have staining in each field (three fields) examined; 4+) 50%-100% tumour cells have staining in each field (three fields) examined. If the staining score was ≥ 2+, we considered this case to be MAYA positive. The positive staining percentages for MAYA over total case number were averaged and shown. For quantification analysis of RNAScope signal and IHC staining, the staining density for each tissue sample was determined by Image-Pro plus 6.0 (Media Cybernetics) and calculated on the basis of the average staining intensity and the percentage of positively stained cells.
In vitro kinase assay. WT or mutant substrate proteins were incubated with 50 µl of in vitro kinase assay buffer I (SignalChem) containing 100 µM ATP (cold reaction) or 10 µCi [γ - 32 P]ATP and the indicated protein kinase for 1 h at 30 • C. To recover the phosphorylated GST-tagged protein, Pierce Glutathione Magnetic Beads (Millipore) were added into reactions and the bound proteins were washed and eluted according to the vendor's instructions. The eluted proteins were dialysed against the appropriate buffers for downstream assays or separated by SDS-PAGE and detected by Coomassie blue staining, autoradiography or immunoblotting.
In vitro methylation assay. Purified recombinant proteins were incubated (1 h, 30 • C) with 1 µg of recombinant FLAG-NSUN6 in 30 µl of methylation buffer (50 mM HEPES pH 8.0, 0.01% (v/v) NP-40, 10 mM NaCl, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride) supplemented with 2 µl of S-adenosyl-
Elmer; for radioactive methylation) or 20 nmol of S-adenosyl-L-methionine sulfate p-toluenesulfonate (SAMe-PTS, Sigma-Aldrich; for non-radioactive methylation). SDS loading buffer was added to methylation reactions and boiled followed by separation on a 4-12% SDS-PAGE gel. The resulting protein bands were visualized by Coomassie blue staining, immunoblotting or autoradiography using EN3HANCE spray (Perkin Elmer).
ChIP and RIP assays, cell proliferation assay, migration and invasion assays.
Cell fixation and chromatin preparation were performed using truChIP Chromatin Shearing Kits on the Covaris M220 focused Ultrasonicator (Covaris). The downstream procedure for ChIP was conducted as previously described 53 . RIP assay, cell proliferation, migration and invasion assays were performed as previously described 34 .
Computational analysis of TCGA RNA-Seq data. We downloaded the breast cancer RNA-seq BAM files from the UCSC Cancer Genomics Hub (CGHub, https://cghub.ucsc.edu). Quantification and statistical analysis of MAYA expression were performed as previously described 34 .
Statistics and reproducibility. The experiment was set up to use 3-5 samples/repeats per experiment/group/condition to detect a twofold difference with a power of 80% and at the significance level of 0.05 by a two-sided test for significant studies. All experiments including IP/IB and immuno-FISH were carried out with three biological replicates. Panels in Figs 1d,h-l, 2l, 4c,k,l, 5h and 8c,d,f-k,m,n and Supplementary Figs 1i-l, 2i-l, 6e-h, 7j and Supplementary Fig. 8d ,e,i-l show a representative image of three independent experiments. Analyses of relative gene expression were determined using the 2-Ct method with GAPDH or B2M as the internal reference genes. The relative quantities of ChIP samples were normalized by individual inputs, respectively. Results are reported as mean ± standard error of the mean (s.e.m.) of at least three independent experiments. Each exact n value is indicated in the corresponding figure legend or in the figure. Statistical analysis was performed using GraphPad Prism 7 software. Comparisons were analysed by twotailed paired Student's t-test, Wilcoxon test or one-way ANOVA test (not significant (NS), P > 0.05, * P < 0.05, * * P < 0.01 and * * * P < 0.001), as indicated in the individual figures. Fisher's exact test was implemented for statistical analyses of the correlation between markers and clinical parameters. For survival analysis, the expression of MAYA or phosphorylation density of indicated proteins was treated as a binary variant and divided into 'high' and 'low' level. Kaplan-Meier survival curves were compared using the log rank test. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
Data availability. The breast cancer RNA-seq data used to analyse MAYA expression were derived from the TCGA Research Network: http://cancergenome.nih.gov, and the breast cancer RNA-seq BAM files were downloaded from the UCSC Cancer Genomics Hub (CGHub, https://cghub.ucsc.edu; also available from http://xena.ucsc.edu/public-hubs/). Source data for all mass spectrometry experiments ( Fig. 2a and Supplementary Figs 2a, 3a, b,e and Supplementary  Fig. 4a ) have been provided as Supplementary Table 2, 3 and Supplementary  Table 5 . Statistics source data for Figs 1d,h-l, 2l, 4c,k-l, 5h and 8c,d,f-k,m,n and Supplementary Figs 1i-l, 2i-l, 6e-h, 7j and 8d ,e,i-l have been provided in Supplementary Table 8 . All other data supporting the findings of this study are available from the corresponding author on request. . For a-c, the boxes show the median±1 quartile, with whiskers extending to the most extreme data point within 1.5 interquartile ranges from the box boundaries. For f, g and i-k, mean ± s.e.m. were derived from n=3 independent experiments (n.s., p>0.05, *p<0.05 and **p<0.01, ***p<0.001, two-tailed paired Student's t-test). Unprocessed original scans of all blots with size marker are shown in Supplementary  Fig. 9 . Statistics source data for i-l are in Supplementary For c-h, mean ± s.e.m. were derived from n=3 independent experiments (n.s., p>0.05, *p<0.05, **p<0.01 and ***p<0.001, two-tailed paired Student's t-test). Unprocessed original scans of all blots with size marker are shown in Supplementary Fig. 9 . Source data for e-h are in Supplementary Table 8 . FLAG-HER3  FLAG-NSUN6  FLAG-SAV1  GST-MST1  GST-LLGL2  GST-RASSF1   His-MOB1   Marker  FLAG-HER3  FLAG-NSUN6  FLAG-SAV1  GST-MST1  GST-LLGL2  GST-RASSF1   His-MOB1   Marker  FLAG-HER3  FLAG-NSUN6  FLAG-SAV1  GST-MST1  GST-LLGL2  GST-RASSF1   His-MOB1   Marker  FLAG-HER3  FLAG-NSUN6  FLAG-SAV1  GST-MST1  GST-LLGL2  GST- 
